{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:24:51Z","timestamp":1791498291645,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vph.2022.106994","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T11:35:20Z","timestamp":1650022520000},"page":"106994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time"],"prefix":"10.1016","volume":"144","author":[{"given":"Francesco","family":"Negro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Casini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ruocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Tripodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2022.106994_bb0005","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2022.106994_bb0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2022.106994_bb0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2022.106994_bb0020","first-page":"1847","article-title":"The 2020 Canadian cardiovascular society\/Canadian Heart Rhythm Society Comprehensive guidelines for the management of Atrial Fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.vph.2022.106994_bb0025","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2022.106994_bb0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2022.106994_bb0035","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","article-title":"Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature","volume":"130","author":"Douxfils","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2022.106994_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2022.106994_bb0045","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.4960170704","article-title":"The use of activated clotting times to monitor heparin therapy during and after interventional procedures","volume":"17","author":"Bowers","year":"1994","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.vph.2022.106994_bb0050","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2022.106994_bb0055","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1053\/j.jvca.2016.09.002","article-title":"Impact of the direct Oral anticoagulants on activated clotting time","volume":"31","author":"Dincq","year":"2017","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/j.vph.2022.106994_bb0060","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/FTD.0000000000000064","article-title":"Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant","volume":"36","author":"Mani","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.vph.2022.106994_bb0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjcard.2014.10.005","article-title":"Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon","volume":"115","author":"Kaess","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.vph.2022.106994_bb0070","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2022.106994_bb0075","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/jth.12308","article-title":"Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels","volume":"11","author":"Hawes","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2022.106994_bb0080","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2022.106994_bb0085","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1093\/eurheartj\/ehz190","article-title":"Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial","volume":"40","author":"Hohnloser","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2022.106994_bb0090","first-page":"495","article-title":"Uninterrupted Dabigatran versus warfarin for ablation in atrial fibrillation","volume":"377","author":"Calkins","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2022.106994_bb0095","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1093\/eurheartj\/ehy176","article-title":"Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation","volume":"39","author":"Kirchhof","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2022.106994_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9020350","article-title":"Activated clotting time monitoring during atrial fibrillation catheter ablation: does the anticoagulant matter?","volume":"9","author":"Martin","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.vph.2022.106994_bb0105","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/joa3.12357","article-title":"Coagulation and heparin requirements during ablation in patients under oral anticoagulant drugs","volume":"36","author":"Maury","year":"2020","journal-title":"J. Arrhythm."},{"key":"10.1016\/j.vph.2022.106994_bb0110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10840-019-00579-y","article-title":"Higher initial weight-based heparin dosing is required with direct oral anticoagulants during catheter ablation for atrial fibrillation","volume":"58","author":"Payne","year":"2020","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"10.1016\/j.vph.2022.106994_bb0115","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/1074248421998492","article-title":"Comprehensive intraprocedural unfractionated heparin protocol during catheter ablation of atrial fibrillation in the presence of direct oral anticoagulants and wide spectrum of body mass index","volume":"26","author":"Safani","year":"2021","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2022.106994_bb0120","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1111\/jce.14260","article-title":"Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes","volume":"30","author":"Yamaji","year":"2019","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.vph.2022.106994_bb0125","doi-asserted-by":"crossref","first-page":"188s","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912200043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912200043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:20:38Z","timestamp":1761528038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153718912200043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":25,"alternative-id":["S153718912200043X"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2022.106994","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2022.106994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106994"}}